Press Release

Press Release

Return to Press Releases

Bicycle Therapeutics Announces Formation Of Scientific Advisory Board

Members include experts in oncology, immunology, and drug discovery and development

CAMBRIDGE, U.K., and CAMBRIDGE, Mass., May 31, 2018 – Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the formation of a Scientific Advisory Board (SAB), comprised of world-leading experts in oncology, immunology, and drug discovery and development. The SAB will work closely with Bicycle’s senior management team to advance the company’s pipeline of Bicycles for the treatment of cancer and other difficult-to-treat diseases.

“The scientific guidance of this group of experts will be invaluable as we develop this novel class of therapies for diseases where existing treatment options are limited,” said Kevin Lee, Ph.D., Bicycle’s Chief Executive Officer. “We look forward to drawing on their extensive expertise as we advance our pipeline of Bicycle Toxin Conjugates, Bicycle targeted innate immune activators, and Bicycle T-cell stimulators.”

The members of Bicycle Therapeutics’ Scientific Advisory Board include:

Additional background on the SAB members can be found on the Bicycle website.

“Bicycle is developing an exciting new class of small molecule medicines for cancer and other serious diseases that promise to be more selective, more potent and less toxic than any other existing modality,” said Sir Gregory Winter, Bicycle’s co-founder, Director and a member of its Scientific Advisory Board. “I am delighted to continue to help guide the company, together with this tremendously accomplished group of scientific leaders, as it continues to advance its robust pipeline of Bicycle product candidates.”

About Bicycle Therapeutics

Bicycle Therapeutics is developing a unique class of chemically synthesised medicines based on its proprietary bicyclic peptide (Bicycle®) product platform to address therapeutic needs unreachable with existing treatment modalities. Bicycle’s internal focus is in oncology, where the company is developing targeted cytotoxics (Bicycle Toxin Conjugates), targeted innate immune activators and T-cell modulators for cancers of high unmet medical need. Bicycles’ small size and exquisite targeting deliver rapid tumour penetration and retention while clearance rates and routes of elimination can be tuned to minimise exposure of healthy tissue and bystander toxicities. The company’s lead program, BT1718, is being evaluated in a Phase I/IIa trial in collaboration with Cancer Research UK. The company’s unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis. Bicycle has its headquarters in Cambridge, U.K., with many key functions and members of its leadership team located in the biotech hub of Boston, Mass. For more information, visit or follow us on Twitter at @Bicycle_tx.


Ten Bridge Communications
Sarah Sutton

Argot Partners
Maeve Conneighton